JP6298823B2 - ＴＧＦβに由来するポリペプチド及びその使用 - Google Patents

ＴＧＦβに由来するポリペプチド及びその使用 Download PDF

Info

Publication number
JP6298823B2
JP6298823B2 JP2015540045A JP2015540045A JP6298823B2 JP 6298823 B2 JP6298823 B2 JP 6298823B2 JP 2015540045 A JP2015540045 A JP 2015540045A JP 2015540045 A JP2015540045 A JP 2015540045A JP 6298823 B2 JP6298823 B2 JP 6298823B2
Authority
JP
Japan
Prior art keywords
tgfβ
polypeptide
tgfβ1
mutein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015540045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535000A (ja
Inventor
オソリオ、アンゲル デ イエズス コルリア
オソリオ、アンゲル デ イエズス コルリア
モンゾン、カレット レオン
モンゾン、カレット レオン
ポルティーリャ、タニア カルメナーテ
ポルティーリャ、タニア カルメナーテ
メリーニョ、アマウリー プーポ
メリーニョ、アマウリー プーポ
ロドリゲス、サウメル ペレス
ロドリゲス、サウメル ペレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6298823(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of JP2015535000A publication Critical patent/JP2015535000A/ja
Application granted granted Critical
Publication of JP6298823B2 publication Critical patent/JP6298823B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015540045A 2012-11-09 2013-10-30 ＴＧＦβに由来するポリペプチド及びその使用 Expired - Fee Related JP6298823B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
CUCU-2012-0158 2012-11-09
CUCU/P/2012/0158 2012-11-09
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018031896A Division JP6608473B2 (ja) 2012-11-09 2018-02-26 ＴＧＦβに由来するポリペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2015535000A JP2015535000A (ja) 2015-12-07
JP6298823B2 true JP6298823B2 (ja) 2018-03-20

Family

ID=49765213

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540045A Expired - Fee Related JP6298823B2 (ja) 2012-11-09 2013-10-30 ＴＧＦβに由来するポリペプチド及びその使用
JP2018031896A Expired - Fee Related JP6608473B2 (ja) 2012-11-09 2018-02-26 ＴＧＦβに由来するポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018031896A Expired - Fee Related JP6608473B2 (ja) 2012-11-09 2018-02-26 ＴＧＦβに由来するポリペプチド及びその使用

Country Status (27)

Country Link
US (1) US9701730B2 (enExample)
EP (1) EP2918284B1 (enExample)
JP (2) JP6298823B2 (enExample)
KR (1) KR102093494B1 (enExample)
CN (1) CN104902916B (enExample)
AR (1) AR093391A1 (enExample)
AU (1) AU2013344022B2 (enExample)
BR (1) BR112015010145B1 (enExample)
CA (1) CA2887455C (enExample)
CL (1) CL2015001252A1 (enExample)
CO (1) CO7400865A2 (enExample)
CU (1) CU24181B1 (enExample)
EA (1) EA031990B1 (enExample)
ES (1) ES2857176T3 (enExample)
IL (1) IL238621B (enExample)
JO (1) JO3502B1 (enExample)
MX (1) MX366060B (enExample)
MY (1) MY173078A (enExample)
NZ (1) NZ707850A (enExample)
PE (1) PE20150890A1 (enExample)
PH (1) PH12015500807A1 (enExample)
SG (1) SG11201502980VA (enExample)
TN (1) TN2015000129A1 (enExample)
TW (1) TWI615404B (enExample)
UA (1) UA115678C2 (enExample)
WO (1) WO2014071894A1 (enExample)
ZA (1) ZA201504462B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018094173A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna
CN119285746A (zh) * 2024-10-24 2025-01-10 湖南中晟全肽生物科技股份有限公司 作为TGF-β受体激动剂肽的化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU778998B2 (en) 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
CA2575278A1 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CN101365712A (zh) * 2005-01-11 2009-02-11 莫勒丘尔洛吉克斯有限公司 Pan-HER拮抗剂及其使用方法
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists

Also Published As

Publication number Publication date
PE20150890A1 (es) 2015-06-10
KR102093494B1 (ko) 2020-03-26
EA201590914A1 (ru) 2015-09-30
AU2013344022B2 (en) 2016-12-15
KR20150083848A (ko) 2015-07-20
TWI615404B (zh) 2018-02-21
CN104902916B (zh) 2018-04-13
ZA201504462B (en) 2018-11-28
CA2887455C (en) 2022-05-17
PH12015500807A1 (en) 2015-06-08
UA115678C2 (uk) 2017-12-11
HK1213781A1 (zh) 2016-07-15
MX2015005875A (es) 2015-09-10
US9701730B2 (en) 2017-07-11
JO3502B1 (ar) 2020-07-05
NZ707850A (en) 2019-08-30
US20150284441A1 (en) 2015-10-08
AU2013344022A1 (en) 2015-05-28
ES2857176T3 (es) 2021-09-28
CL2015001252A1 (es) 2015-07-17
SG11201502980VA (en) 2015-06-29
EA031990B1 (ru) 2019-03-29
CN104902916A (zh) 2015-09-09
EP2918284A1 (en) 2015-09-16
JP2018111703A (ja) 2018-07-19
CU20120158A7 (es) 2014-06-27
TN2015000129A1 (en) 2016-10-03
TW201431875A (zh) 2014-08-16
MY173078A (en) 2019-12-25
CU24181B1 (es) 2016-04-25
JP6608473B2 (ja) 2019-11-20
JP2015535000A (ja) 2015-12-07
IL238621B (en) 2019-12-31
CO7400865A2 (es) 2015-09-30
CA2887455A1 (en) 2014-05-15
MX366060B (es) 2019-06-26
EP2918284B1 (en) 2021-02-17
WO2014071894A1 (es) 2014-05-15
AR093391A1 (es) 2015-06-03
BR112015010145A2 (enExample) 2017-08-22
IL238621A0 (en) 2015-06-30
BR112015010145B1 (pt) 2022-06-07

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
US20230381276A1 (en) Interleukin-21 mutein/ anti-pd-1 antibody conjugates
JP7767290B2 (ja) 新規なマスクされたサイトカインおよびその使用方法
RU2517596C2 (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ
US11518808B2 (en) Anti-PD-1 antibodies and methods of treatment
Gadó et al. Role of interleukin‐6 in the pathogenesis of multiple myeloma
US7947265B2 (en) Fusion proteins and methods for modulation of immune response
EP2639241B1 (en) Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
Joshi et al. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect
Hsu et al. Anti–IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss
CN114401997A (zh) 细胞因子前药和双前药
JP6608473B2 (ja) ＴＧＦβに由来するポリペプチド及びその使用
Kusters et al. Cytokines and immune responses in murine atherosclerosis
HK1213781B (en) POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
CN118974093A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
HK40029717A (en) Interleukin-21 muteins and methods of treatment
HK40029717B (en) Interleukin-21 muteins and methods of treatment

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180226

R150 Certificate of patent or registration of utility model

Ref document number: 6298823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees